Abstract
Denosumab is a fully human monoclonal antibody, the first RANKL inhibitor to be approved by the FDA, now available for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma and giant cell tumour of the bone. Precursors of osteoclasts, called pre-osteoclasts, express the surface receptor RANK (receptor activator of nuclear factor kappa B), a member of the tumour necrosis factor receptor (TNFR) family. RANK is activated by the ligand RANKL, which are cell surface molecules on osteoblasts. Activation of RANK by RANKL promotes the differentiation of pre-osteoclasts to active osteoclasts. Denosumab inhibits this maturation of osteoclasts by binding to and inhibiting RANKL. This reaction mimics the natural action of osteoprotegerin (OPG) and protects the bone from resorption.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Bartl, R., Bartl, C. (2019). Other Drugs in Osteoporosis. In: The Osteoporosis Manual. Springer, Cham. https://doi.org/10.1007/978-3-030-00731-7_25
Download citation
DOI: https://doi.org/10.1007/978-3-030-00731-7_25
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-00730-0
Online ISBN: 978-3-030-00731-7
eBook Packages: MedicineMedicine (R0)